Horizon Therapeutics and Nitec Pharma Complete Merger and Combine Businesses

Combined company has one approved product in Europe (LODOTRA(R)) and two late-stage U.S. product candidates in pain management and rheumatoid arthritis -

NORTHBROOK, Illinois and REINACH, Switzerland, April 1, 2010 - Horizon Therapeutics, Inc. and Nitec Pharma AG, both privately held
companies, today announced a definitive agreement in which the two companies
have combined in an all-stock transaction. The combined company also
completed a concurrent preferred stock financing in conjunction with the
transaction.

The combined company will be named Horizon Pharma, Inc., and will be led
by Timothy P. Walbert, previously president and chief executive of Horizon
Therapeutics. The company will be headquartered in Northbrook, IL, with
offices in Reinach, Switzerland (Horizon Pharma AG) and Mannheim, Germany
(Horizon Pharma GmbH).

"This combination provides immediate strategic value by strengthening and
diversifying our potential product portfolio, as well as providing greater
access to the U.S. capital markets," said Timothy P. Walbert, chairman,
president and chief executive officer, Horizon Pharma, Inc. "With LODOTRA(R)
marketed in Europe and anticipated U.S. new drug application (NDA)
submissions for both DUEXA(R) and LODOTRA in 2010, we are optimistic that we
will be able to provide patients and physicians with new treatment options in
pain management and chronic inflammatory diseases."

Company Portfolio

The combined company now has two late-stage U.S. product candidates in
development. One of them, LODOTRA, has been approved and is marketed in
Europe.

LODOTRA, a novel single-pulse delayed-release (SPDR) low-dose prednisone
tablet, was first launched in Germany in April 2009, and is currently being
marketed for the reduction in morning stiffness associated with rheumatoid
arthritis (RA). A European Phase 3 trial of LODOTRA in rheumatoid arthritis
(RA) was completed in 2006 and a marketing authorization application was
submitted to 15 Member States of the European Union using the Decentralized
Procedure with Germany as Reference Member State. The procedure was completed
in December 2008, resulting in the recommendation to grant a national
marketing authorization of LODOTRA for the treatment of RA and associated
morning stiffness in the Reference Member State and the other 14 Concerned
Member States, namely Austria, Belgium, Denmark, Finland, France, Italy,
Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, Sweden, and the
United Kingdom.

Merck KGaA holds marketing rights to LODOTRA in Germany and Austria, and
Mundipharma holds marketing rights to LODOTRA in the rest of Europe.

The company has completed a Phase 3 trial for LODOTRA in the U.S. for the
treatment of the signs and symptoms of RA. In the pivotal U.S. Phase 3
clinical study (CAPRA-2), patients treated with LODOTRA experienced a
statistically significant improvement in ACR-20 response when compared with
patients in the placebo group (48.5 percent vs. 28.6 percent; p=0.0002). In
addition, patients taking LODOTRA experienced a statistically significant
improvement in ACR-50 response (22.7 percent vs. 9.2 percent; p=0.0027).
Importantly, patients treated with LODOTRA also experienced a statistically
significant reduction in morning stiffness when compared with patients in the
placebo group (44 percent vs. 21 percent; p=0.0008).

LODOTRA is also being investigated for the treatment of severe asthma and
polymyalgia rheumatica (PMR).

DUEXA, formerly HZT-501, is a novel, proprietary tablet formulation
containing a fixed-dose combination of ibuprofen, one of the world's most
prescribed non-steroidal anti-inflammatory drugs (NSAID), with high-dose
famotidine, the most potent H2 antagonist. In two Phase 3 clinical studies
(REDUCE-1 and REDUCE-2), DUEXA was shown to significantly reduce the
incidence of NSAID-induced upper gastrointestinal (GI) ulcers in patients
with mild-to-moderate pain and arthritis. The trials were conducted in the
U.S. via a Special Protocol Assessment (SPA) with the U.S. Food and Drug
Administration (FDA) and enrolled more than 1,500 patients.

Horizon recently submitted an NDA for DUEXA to the FDA and expects an FDA
decision on acceptance for review in the 2nd quarter of 2010. The Company
also anticipates it will submit an NDA for LODOTRA to the U.S. FDA in the
second half of 2010 and anticipates submitting a marketing authorization
application (MAA) for DUEXA in the European Union through the Decentralized
Procedure in the second half of 2010.

Other product candidates in the combined company's development pipeline
include: HZN-602 (naproxen/famotidine), a combination oral drug consisting of
immediate-release naproxen with high-dose famotidine, being investigated for
the reduction of the risk of upper gastrointestinal (GI) ulcers in patients
with pain and arthritis; and TruNoc(TM) (tarenflurbil), which is under
investigation as a potential treatment for pain-related diseases.

The combined company holds worldwide commercialization rights for its
products and product candidates, other than the distribution rights granted
for LODOTRA in Europe.

About the Transaction

In the completed transaction, Horizon Therapeutics and Nitec Pharma
exchanged shares into a new holding company, Horizon Pharma, Inc. Horizon
Therapeutics, Inc. is now a subsidiary of Horizon Pharma, Inc. and has been
renamed Horizon Pharma USA, Inc. and Nitec Pharma AG is now a subsidiary of
Horizon Pharma, Inc. and will be renamed Horizon Pharma AG. Nitec's German
subsidiary, Nitec Pharma GmbH will be renamed Horizon Pharma GmbH. Bank of
America Merrill Lynch acted as financial advisor and Cooley Godward Kronish
LLP was legal counsel to Horizon in the transaction. JMP Securities LLC acted
as financial advisor and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
served as legal counsel to Nitec in the transaction.

About Horizon Pharma

Horizon Pharma, Inc. is a late-stage biopharmaceutical company focused on
the development and commercialization of innovative medicines for
pain-related diseases and chronic inflammation. Horizon Pharma's product
portfolio includes innovative therapies in early- and late-stage development
that are designed to improve the efficacy, safety and quality of life for
patients with chronic pain and inflammation. Horizon's most advanced product
is LODOTRA, a circadian cytokine modulator (CCM) for the treatment of
rheumatoid arthritis (RA), which has received a recommendation for granting
of a national marketing authorization in certain Member States of the
European Union. LODOTRA is already launched in Germany. The Company is
financed by leading life-science investors Atlas Venture, Deutsche Bank AG,
London, Essex Woodlands Healthcare Ventures, FirstMark Capital, Global Life
Science Ventures, NGN Capital, Scale Ventures, Sutter Hill Ventures and TVM
Capital.

For more information about the company and its products, please visit
www.horizon-pharma.com.

Forward Looking Statements

This press release includes forward-looking statements that are subject
to risks, uncertainties and other factors. All statements other than
statements of historical fact are statements that could be deemed
forward-looking statements, including, but not limited to, statements
regarding the ability of the combined company to realize the anticipated
benefits of the combination; any statements regarding the future of any
product or product candidate, including the submission of such products or
product candidates for approval; and any statements of the plans, strategies
and objectives of management for future operations of the combined company.
Such statements are only predictions, and actual events or results may differ
materially from those projected in such forward-looking statements. Factors
that could cause or contribute to the differences include, but are not
limited to, risks associated with the ability of the combined company to
achieve any benefit resulting from the combination, risks associated with
operations conducted in multiple jurisdictions, the inherent risks of product
development and approval, clinical outcomes, regulatory risks, risks related
to proprietary rights, market acceptance and competition and risks associated
with the combined company's ability to obtain additional capital to support
its planned operations.

Robert J. De Vaere, Executive Vice President, Chief Financial Officer of Horizon Pharma, Inc., +1-760-436-4010, bdevaere at horizon-pharma.com; or Geoff Curtis of WCG, +1-312-646-6298, gcurtis at wcgworld.com, for Horizon Pharma, Inc.